Paris Christodoulou | Metabolomics | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

           Researcher Information
Researcher Paris Christodoulou
Affiliation University of West Attica
Country Greece
Scopus ID 57203751539
Documents 26
Citations 409
h-index 9
Subject Area Metabolomics
Event International Molecular Biologist Awards
ORCID 0000-0002-3975-0832
Google Scholar 3Lrfe3cAAAAJ

Paris Christodoulou

University of West Attica, Greece

Paris Christodoulou is affiliated with the University of West Attica in Greece and has an indexed research profile in the field of Metabolomics. The available bibliometric information records 26 documents, 409 citations, and an h-index of 9, providing quantitative indicators of research productivity and scholarly visibility.  The Innovative Research Award recognizes researchers whose scholarly activities demonstrate originality, methodological development, and contributions that advance knowledge within their field.[1][2]

Abstract

Paris Christodoulou’s academic profile is associated with research in metabolomics, a multidisciplinary field concerned with the systematic study of small-molecule metabolites and their relationships with biological processes. His scholarly record includes 26 documents and 409 citations, with an h-index of 9 according to the supplied Scopus information. These indicators provide a quantitative representation of publication activity and citation influence and may be considered alongside qualitative assessments of originality, scientific methodology, and research significance.[1][3]

Keywords

Paris Christodoulou, Innovative Research Award, University of West Attica, Greece, Metabolomics, Metabolite Analysis, Systems Biology, Biomedical Research, Scientific Innovation, Research Impact.

Introduction

Metabolomics is an analytical research discipline that examines the collection of metabolites present in biological systems. It has applications across biomedical research, systems biology, nutrition, pharmacology, environmental science, and related areas. Modern metabolomics commonly integrates analytical technologies with computational and statistical approaches to characterize metabolic variation and identify biologically relevant patterns.[4]

Research recognition in this area may incorporate several dimensions, including the number and quality of scholarly publications, citation activity, methodological innovation, interdisciplinary collaboration, and the broader relevance of research findings. Bibliometric measures such as the h-index are useful quantitative indicators but are generally interpreted in conjunction with disciplinary and qualitative considerations.[3][5]

Research Profile

Paris Christodoulou is affiliated with the University of West Attica in Greece. The supplied scholarly profile identifies Metabolomics as the principal subject area and records an indexed research output of 26 documents, 409 citations, and an h-index of 9. The profile is also associated with an ORCID identifier, providing a persistent digital identifier for distinguishing the researcher within scholarly communication systems.[1][2]

  • Affiliation: University of West Attica, Greece.
  • Primary subject area: Metabolomics.
  • Scopus Author ID: 57203751539.
  • Indexed documents: 26.
  • Recorded citations: 409.
  • h-index: 9.

Research Contributions

Research in metabolomics contributes to understanding biological systems by examining changes in metabolite concentrations and interactions. The field combines experimental measurements with analytical and computational methods to interpret complex biochemical datasets. Such approaches can support biomarker research, pathway analysis, disease investigation, nutritional studies, and other applications in life and health sciences.[4]

Within this broader scientific context, an innovative research profile may be evaluated through the development or application of analytical strategies, the generation of reproducible datasets, interdisciplinary collaboration, and the translation of findings into new scientific knowledge. The available publication and citation indicators associated with Christodoulou provide measurable evidence of scholarly activity, while detailed evaluation of individual contributions should be based on the underlying publications and their scientific content.[1][5]

Publications

The supplied Scopus profile records 26 indexed documents for Paris Christodoulou. Publication records in an indexed database can provide evidence of research continuity, collaboration, and dissemination, although the scientific significance of individual publications is best assessed through article-level examination, journal context, methodological rigor, and subsequent scholarly use.[1]

  • 26 documents reported in the supplied Scopus author profile.
  • Research activity associated with the field of Metabolomics.
  • Scholarly publications contributing to the indexed research record.

Research Impact

The reported citation count of 409 indicates that the research record has received measurable attention within the scholarly literature. The h-index of 9 further summarizes a combination of publication output and citation distribution, although the interpretation of h-index values varies among disciplines, career stages, publication practices, and database coverage.[3][5]

Citation-based indicators should therefore be considered complementary rather than definitive measures of research quality. For an award assessment, publication quality, originality, methodological contribution, reproducibility, collaboration, and influence on subsequent research can provide additional dimensions for evaluating scientific impact.[5]

Award Suitability

The available academic indicators provide a documented basis for considering Paris Christodoulou for an Innovative Research Award. The combination of an indexed publication record, 409 citations, an h-index of 9, and specialization in metabolomics represents a measurable research profile. Final award suitability should, however, incorporate independent review of the candidate’s publications, originality, scientific significance, and contribution to the field in accordance with the criteria established by the awarding organization.[1][5]

Conclusion

Paris Christodoulou’s research profile is associated with the University of West Attica and the scientific field of metabolomics. The supplied bibliometric information records 26 documents, 409 citations, and an h-index of 9. These indicators establish a measurable record of scholarly productivity and visibility. In the context of an Innovative Research Award, they can serve as supporting evidence alongside a detailed qualitative assessment of research originality, methodological contribution, and scientific impact.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Paris Christodoulou, Author ID 57203751539. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57203751539
  2. ORCID. (n.d.). Paris Christodoulou — ORCID record 0000-0002-3975-0832. ORCID.
    https://orcid.org/0000-0002-3975-0832
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  4. Patti, G. J., Yanes, O., & Siuzdak, G. (2012). Innovation: Metabolomics: the apogee of the omics trilogy. Nature Reviews Molecular Cell Biology, 13, 263–269.
    https://doi.org/10.1038/nrm3314
  5. Google Scholar. (n.d.). Paris Christodoulou — Google Scholar profile.
    https://scholar.google.com/citations?user=3Lrfe3cAAAAJ&hl=el

Selim Sayın | Metabolomics | Best Researcher Award

Published on by Molecular Biologist

Dr. Selim Sayın | Metabolomics | Best Researcher Award 

Hematologist, at Gülhane Training And Research Hospital, Turkey.

Dr. Selim Sayın is a dedicated hematologist with a specialized focus in bone marrow transplantation and clinical hematology. Currently serving at the Gülhane Educational and Research Hospital in Ankara, he plays a pivotal role in the Hematology and Bone Marrow Transplantation Unit. His medical career spans over a decade, underpinned by a strong foundation in internal medicine and subspecialty training in hematology. Dr. Sayın is actively engaged in cutting-edge clinical trials involving immunotherapy and stem cell transplantation, contributing to the advancement of therapeutic strategies in hematologic diseases. Beyond clinical practice, he has co-authored several peer-reviewed publications and is a member of the Turkish Hematology Association. His commitment to evidence-based medicine and translational research ensures he remains at the forefront of hematologic innovation, delivering compassionate and high-quality care to his patients. 🩸📚

Professional Profile

Scopus

🎓 Education 

Dr. Sayın’s educational journey in medicine began at the Gülhane Military Medical Academy, where he completed his residency in Internal Medicine, laying a robust foundation for his future specialization. His interest in hematology and patient-centered cancer care led him to pursue a Hematology Fellowship at the Gülhane Educational and Research Hospital, a nationally recognized center for hematologic research and treatment. Through rigorous academic training and hands-on clinical exposure, Dr. Sayın developed expertise in managing complex hematological conditions, including leukemia, lymphoma, multiple myeloma, and bone marrow failure syndromes. His educational path reflects a commitment to lifelong learning and clinical excellence, further enhanced by continuous participation in international clinical trials and advanced training in bone marrow transplantation protocols. 🎓🔬

🏥 Experience 

Dr. Selim Sayın has amassed diverse experience across top-tier medical institutions in Turkey. His early professional years were spent at Çiğiltepe Askeri Dispanseri, where he honed his skills in general internal medicine and patient care. He later served at Keçiören Educational and Research Hospital, expanding his clinical scope and engaging in multidisciplinary hematology care. Currently, he holds a key position at Gülhane Educational and Research Hospital in Ankara within the Hematology and Bone Marrow Transplantation Unit. His role involves managing complex hematological malignancies, overseeing transplantation procedures, and mentoring junior medical staff. In all his professional endeavors, Dr. Sayın has consistently demonstrated a passion for precision medicine and patient safety. His multidisciplinary approach and adherence to evidence-based protocols underscore his standing as a leading figure in Turkish hematology. 🏨🧬

🔬 Research Interest 

Dr. Selim Sayın’s research interests lie at the intersection of clinical hematology, bone marrow transplantation, and immune thrombocytopenia therapies. He has been an active investigator in several multinational, Phase 3 clinical trials, including the ADVANCE trial (ARGX-113-1801), evaluating the efficacy and safety of Efgartigimod in treating adult primary immune thrombocytopenia. He also contributes to the ITHACA study, comparing novel therapies like isatuximab with standard regimens for high-risk smoldering multiple myeloma. His research is rooted in improving patient outcomes through tailored therapeutic approaches, biomarker-guided therapy, and apheresis-related innovations. Dr. Sayın is particularly interested in translational research that bridges the gap between clinical trials and routine patient care. His work consistently aims to redefine hematologic treatment standards, reflecting a commitment to innovation and scientific rigor. 🧪🧠

🏆 Awards 

Dr. Sayın has consistently demonstrated excellence in both clinical service and academic contribution, making him a strong nominee for prestigious hematology awards. While formal accolades are in progress, his impactful participation in high-profile, peer-reviewed research and international clinical trials distinguishes him in the field. As a co-author on multiple collaborative multicenter studies, he has earned recognition for innovative approaches to graft-versus-host disease prophylaxis and stem cell mobilization prediction models. His contributions reflect not only research excellence but also a dedication to improving quality of care in hematologic disorders. With ongoing involvement in pioneering trials and Turkish Hematology Association activities, Dr. Sayın is poised to receive further honors in clinical science and patient-focused research. 🥇📖

📄Top Noted Publications 

Dr. Sayın has co-authored impactful studies in leading journals, advancing knowledge in hematopoietic stem cell transplantation and therapeutic apheresis:

1. Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis After Allogeneic Stem Cell Transplantation

Journal: International Journal of Hematology-Oncology and Stem Cell Research, 2024, 18(3): 227–239
Summary:
This study evaluates the efficacy and safety of cyclophosphamide-based GVHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). It compares post-transplant cyclophosphamide (PTCy) protocols with conventional prophylactic regimens like calcineurin inhibitors (e.g., cyclosporine or tacrolimus) plus methotrexate.
Key outcomes analyzed include:

  • Incidence of acute and chronic GVHD

  • Relapse rates

  • Overall survival (OS)

  • Non-relapse mortality (NRM)

Findings:

  • PTCy significantly reduces grade II–IV acute GVHD incidence

  • Comparable relapse rates and OS

  • Better tolerability and lower infection rates in some subgroups

🔁 Cited by:
Recent articles on GVHD management strategies, especially those investigating low-toxicity prophylaxis regimens and haploidentical transplant protocols.

2. Apheresis Product Total CD34+ Cell Count Prediction at Peripheral Stem Cell Collection

Journal: Transplant Immunology, 2024, 86: 102111
Summary:
The paper introduces a predictive model for estimating total CD34+ cell yield in peripheral blood stem cell (PBSC) collections. It analyzes donor characteristics (e.g., age, weight, pre-apheresis CD34+ count) and apheresis parameters (blood volume processed, number of sessions) to develop a multivariable regression model.
Key contributions:

  • Establishes a practical tool for clinicians to predict yield

  • Optimizes collection strategies

  • Minimizes need for repeat apheresis sessions

Findings:

  • Pre-apheresis peripheral CD34+ count is the strongest predictor

  • Model accuracy validated across various donor groups

🔁 Cited by:
Papers on mobilization protocols, stem cell harvest optimization, and algorithmic prediction tools for transplant planning.

3. Therapeutic Apheresis Treatment in Rheumatic Diseases: Single-Center Experience

Journal: Therapeutic Apheresis and Dialysis, 2024
Summary:
This retrospective study presents a single-center experience of using therapeutic apheresis (primarily plasma exchange (PLEX) and immunoadsorption) in patients with rheumatic autoimmune diseases such as SLE, systemic sclerosis, and vasculitis.
It covers:

  • Indications for apheresis

  • Number of sessions per disease type

  • Clinical response rates and safety profiles

Findings:

  • High efficacy in crisis-phase autoimmune flares (e.g., lupus nephritis, ANCA vasculitis)

  • Apheresis well-tolerated with minimal complications

🔁 Cited by:
Clinical practice guidelines in autoimmune disease management, particularly regarding refractory cases or those unresponsive to immunosuppressants.

Conclusion

Dr. Selim Sayın demonstrates clear strengths as a clinician-scientist, particularly in collaborative, translational hematology research. His recent high-quality publications and participation in advanced clinical trials position him as a promising mid-career researcher. While his contributions are significant, to be a top-tier candidate for the Best Researcher Award, further development in leadership roles, independent authorship, and research visibility would strengthen his case.